keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
Published 3 years ago • 397 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
4:23
keynote-407: 3-year follow-up of pembrolizumab plus chemo in nsclc
-
3:44
pembrolizumab plus chemo shows prolonged os and pfs improvement vs chemo for squamous nsclc
-
6:00
ramucirumab plus pembrolizumab improves os in advanced nsclc
-
3:29
squamous cell frontline therapy: impower 131, keynote-407
-
7:13
first-line pembrolizumab plus chemotherapy for patients with advanced squamous nsclc: 3-year fol...
-
4:52
the keynote-407 trial in metastatic squamous nsclc
-
3:37
pembrolizumab plus chemo as firstline therapy for nsclc
-
4:17
blood tumour mutational burden and response to pembrolizumab plus chemotherapy in non-small cell...
-
7:01
actual use of pembrolizumab and chemotherapy in nsclc
-
4:28
combining chemotherapy and immunotherapy: key trials in lung cancer
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
0:54
dr. bestvina on the keynote-407 trial in squamous nsclc
-
3:44
pembro plus chemo followed by resection and adjuvant pembro improves on soc for early nsclc
-
2:21
ea5163/s1709/insigna: the timing of pembrolizumab /- chemo as 1l treatment and maintenance in nsclc
-
2:44
pembrolizumab and chemotherapy in advanced nsclc
-
2:23
pembrolizumab plus chemotherapy for esophageal cancer: keynote-590
-
3:13
latest data from keynote 42: pembrolizumab vs chemotherapy in treatment-naive patients (pts) wit...
-
3:48
poseidon: durvalumab /- tremelimumab chemo in 1l mnsclc
-
1:23
dr. burtness on the benefit of pembrolizumab in head and neck cancer